NCT01368848 - Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

NSCLC

Interventions

DRUG

Bevacizumab

"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W -\> Bevacizumab Q3W until progression"

DRUG

Cisplatin

"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"

DRUG

Docetaxel

"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"

Trial Locations (3)

5020

Universitaetsklinik der PMU Salzburg, UK f. Innere Medizin III, Salzburg

6020

Univ.-Klinik für Innere Medizin V Innsbruck, Abteilung für Hämatologie und Onkologie, Innsbruck

6806

Landeskrankenhaus Feldkirch, Feldkirch